Diane Chen1, Mere Abrams2, Leslie Clark3, Diane Ehrensaft2, Amy C Tishelman4, Yee-Ming Chan5, Robert Garofalo6, Johanna Olson-Kennedy3, Stephen M Rosenthal2, Marco A Hidalgo3. 1. Gender & Sex Development Program, Potocsnak Family Division of Adolescent and Young Adult Medicine, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois; Pritzker Department of Psychiatry and Behavioral Health, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois; Department of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine, Chicago, Illinois; Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois. Electronic address: DiChen@luriechildrens.org. 2. Child & Adolescent Gender Center, Benioff Children's Hospital, University of California, San Francisco, California; Division of Pediatric Endocrinology, Department of Pediatrics, University of California San Francisco, San Francisco, California. 3. Division of Adolescent and Young Adult Medicine, Center for Transyouth Health and Development, Children's Hospital Los Angeles, Los Angeles, California; Department of Pediatrics, Keck School of Medicine, University of Southern California, Los Angeles, California. 4. Division of Endocrinology, Boston Children's Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts; Department of Psychiatry, Boston Children's Hospital, Boston, Massachusetts. 5. Division of Endocrinology, Boston Children's Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts. 6. Gender & Sex Development Program, Potocsnak Family Division of Adolescent and Young Adult Medicine, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois; Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Abstract
PURPOSE: This study aimed to characterize two developmental cohorts of transgender and nonbinary youth enrolled in the Trans Youth Care Network Study and describe their gender identity-related milestones and baseline mental health and psychosocial functioning. METHODS: Trans Youth Care participants were recruited from four pediatric academic medical centers in the U.S. before initiating medical treatment for gender dysphoria either with gonadotropin-releasing hormone agonists (GnRHa) or gender-affirming hormones (GAH). GnRHa cohort data were collected from youth and a parent; GAH cohort data were collected from youth only. RESULTS: A total of 95 youth were enrolled in the GnRHa cohort. Mean age was 11.22 years (standard deviation = 1.46), and the majority were white (52.6%) and designated male at birth (51.6%). Elevated depression symptoms were endorsed by 28.6% of GnRHa cohort youth, and 22.1% endorsed clinically significant anxiety. Approximately one fourth (23.6%) endorsed lifetime suicidal ideation, with 7.9% reporting a past suicide attempt. A total of 316 youth were enrolled in the GAH cohort. The mean age was 16.0 years (standard deviation = 1.88), and the majority were white (62%) and designated female at birth (64.9%). Elevated depression symptoms were endorsed by 51.3% of the GAH cohort, and 57.3% endorsed clinically significant anxiety. Two-thirds (66.6%) endorsed lifetime suicidal ideation, with 24.6% reporting a past suicide attempt. Life satisfaction was lower among both cohorts compared with population-based norms. CONCLUSIONS: GnRHa cohort youth appear to be functioning better from a psychosocial standpoint than GAH cohort youth, pointing to possible benefits of accessing gender-affirming treatment earlier in life.
PURPOSE: This study aimed to characterize two developmental cohorts of transgender and nonbinary youth enrolled in the Trans Youth Care Network Study and describe their gender identity-related milestones and baseline mental health and psychosocial functioning. METHODS: Trans Youth Care participants were recruited from four pediatric academic medical centers in the U.S. before initiating medical treatment for gender dysphoria either with gonadotropin-releasing hormone agonists (GnRHa) or gender-affirming hormones (GAH). GnRHa cohort data were collected from youth and a parent; GAH cohort data were collected from youth only. RESULTS: A total of 95 youth were enrolled in the GnRHa cohort. Mean age was 11.22 years (standard deviation = 1.46), and the majority were white (52.6%) and designated male at birth (51.6%). Elevated depression symptoms were endorsed by 28.6% of GnRHa cohort youth, and 22.1% endorsed clinically significant anxiety. Approximately one fourth (23.6%) endorsed lifetime suicidal ideation, with 7.9% reporting a past suicide attempt. A total of 316 youth were enrolled in the GAH cohort. The mean age was 16.0 years (standard deviation = 1.88), and the majority were white (62%) and designated female at birth (64.9%). Elevated depression symptoms were endorsed by 51.3% of the GAH cohort, and 57.3% endorsed clinically significant anxiety. Two-thirds (66.6%) endorsed lifetime suicidal ideation, with 24.6% reporting a past suicide attempt. Life satisfaction was lower among both cohorts compared with population-based norms. CONCLUSIONS: GnRHa cohort youth appear to be functioning better from a psychosocial standpoint than GAH cohort youth, pointing to possible benefits of accessing gender-affirming treatment earlier in life.
Authors: Annelou L C de Vries; Thomas D Steensma; Theo A H Doreleijers; Peggy T Cohen-Kettenis Journal: J Sex Med Date: 2010-07-14 Impact factor: 3.802
Authors: Wylie C Hembree; Peggy T Cohen-Kettenis; Louis Gooren; Sabine E Hannema; Walter J Meyer; M Hassan Murad; Stephen M Rosenthal; Joshua D Safer; Vin Tangpricha; Guy G T'Sjoen Journal: J Clin Endocrinol Metab Date: 2017-11-01 Impact factor: 5.958
Authors: Tracy A Becerra-Culqui; Yuan Liu; Rebecca Nash; Lee Cromwell; W Dana Flanders; Darios Getahun; Shawn V Giammattei; Enid M Hunkeler; Timothy L Lash; Andrea Millman; Virginia P Quinn; Brandi Robinson; Douglas Roblin; David E Sandberg; Michael J Silverberg; Vin Tangpricha; Michael Goodman Journal: Pediatrics Date: 2018-04-16 Impact factor: 7.124
Authors: Sari L Reisner; Ralph Vetters; M Leclerc; Shayne Zaslow; Sarah Wolfrum; Daniel Shumer; Matthew J Mimiaga Journal: J Adolesc Health Date: 2015-01-07 Impact factor: 5.012
Authors: Amanda E Guyer; Jennifer Y F Lau; Erin B McClure-Tone; Jessica Parrish; Nina D Shiffrin; Richard C Reynolds; Gang Chen; R J R Blair; Ellen Leibenluft; Nathan A Fox; Monique Ernst; Daniel S Pine; Eric E Nelson Journal: Arch Gen Psychiatry Date: 2008-11
Authors: Maureen D Connolly; Marcus J Zervos; Charles J Barone; Christine C Johnson; Christine L M Joseph Journal: J Adolesc Health Date: 2016-08-17 Impact factor: 5.012
Authors: Rosalia Costa; Michael Dunsford; Elin Skagerberg; Victoria Holt; Polly Carmichael; Marco Colizzi Journal: J Sex Med Date: 2015-11-09 Impact factor: 3.802
Authors: Emily W Paolillo; Benjamin S McKenna; Cindy J Nowinski; Michael L Thomas; Vanessa L Malcarne; Robert K Heaton Journal: Assessment Date: 2018-04-05
Authors: Michelle M Johns; Richard Lowry; Jack Andrzejewski; Lisa C Barrios; Zewditu Demissie; Timothy McManus; Catherine N Rasberry; Leah Robin; J Michael Underwood Journal: MMWR Morb Mortal Wkly Rep Date: 2019-01-25 Impact factor: 17.586
Authors: Annelou L C de Vries; Christina Richards; Amy C Tishelman; Joz Motmans; Sabine E Hannema; Jamison Green; Stephen M Rosenthal Journal: Int J Transgend Health Date: 2021-04-05
Authors: John F Strang; Diane Chen; Eric Nelson; Scott F Leibowitz; Leena Nahata; Laura G Anthony; Amber Song; Connor Grannis; Elizabeth Graham; Shane Henise; Eric Vilain; Eleonora Sadikova; Andrew Freeman; Cara Pugliese; Ayesha Khawaja; Tekla Maisashvili; Michael Mancilla; Lauren Kenworthy Journal: Child Psychiatry Hum Dev Date: 2021-06-19